Clot removal device for recent pulmonary embolism
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial tests a device that removes blood clots from the lungs in people with a recent pulmonary embolism. It may help improve blood flow and reduce strain on the heart.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have symptoms of a pulmonary embolism (blood clot in the lung) that started within the last 14 days.
- A CT scan shows a clot in a large lung artery and your heart is working harder than normal (RV/LV ratio ≥ 0.9).
- Your blood pressure is stable (systolic 90 or above) without needing strong medications.
- You have not had a stroke or major bleeding risk, and you do not have severe kidney, liver, or bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a device called the FlowTriever to remove blood clots from the lungs in people with a pulmonary embolism that is not too severe. The goal is to see if this treatment can help improve heart function and symptoms without major surgery.
This study tests a new device (AlphaVac) that removes blood clots from the lungs using a thin tube inserted through a vein. It may be an option for people with acute pulmonary embolism who have signs of heart strain or low blood pressure.
This Phase 3 trial tests a catheter-based procedure to remove a lung blood clot (pulmonary embolism) and reduce strain on the heart. It may help people who have specific CT scan signs of right-heart strain.
This trial tests a new treatment for people with a severe, high-risk pulmonary embolism (blood clot in the lung). It uses a catheter device to remove the clot and help the heart work better.
This trial tests a treatment that uses ultrasound to guide a thin tube (catheter) to deliver clot-busting medicine directly into the blood clot in your lung. It may be an option for people whose clot is serious but not yet causing shock, and who have symptoms that started within the last two weeks.
This study tests a new way of delivering a clot-dissolving medicine for people with a serious but not immediately life-threatening pulmonary embolism. The goal is to see if giving the medicine as small bursts directly into the clot can help the heart recover faster.
Hear when a new Pulmonary Embolism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.